Drug Profile
Research programme: cancer vaccines - CureVac/Eli Lilly and Company
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator CureVac
- Developer CureVac; Eli Lilly and Company
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 12 Feb 2020 Preclinical trials in Cancer in Germany (Parenteral) (CureVac pipeline, February 2020)
- 24 Jan 2018 CureVac has patent protection for its cancer vaccine programme in Europe